Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H43N13O10 |
Molecular Weight | 685.69 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(C[C@H](O)NC(N)=N1)[C@]2([H])NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CNC2=O)NC(=O)C[C@@H](N)CCCN)=C\NC(N)=O
InChI
InChIKey=GXFAIFRPOKBQRV-GHXCTMGLSA-N
InChI=1S/C25H43N13O10/c26-3-1-2-10(27)4-16(41)32-12-6-30-23(47)18(11-5-17(42)37-24(28)36-11)38-20(44)13(7-31-25(29)48)33-21(45)14(8-39)35-22(46)15(9-40)34-19(12)43/h7,10-12,14-15,17-18,39-40,42H,1-6,8-9,26-27H2,(H,30,47)(H,32,41)(H,33,45)(H,34,43)(H,35,46)(H,38,44)(H3,28,36,37)(H3,29,31,48)/b13-7-/t10-,11+,12-,14-,15-,17-,18-/m0/s1
DescriptionCurator's Comment: Description was created based on several sources, including
https://books.google.ru/books?id=JxElBQAAQBAJ&pg=PA421&lpg=PA421&dq=VIOMYCIN retrieved from Antibiotics: Origin, Nature and Properties
Tadeusz Korzybski,Zuzanna Kowszyk-Gindifer,Wlodzimierz Kurylowicz, p. 421
Curator's Comment: Description was created based on several sources, including
https://books.google.ru/books?id=JxElBQAAQBAJ&pg=PA421&lpg=PA421&dq=VIOMYCIN retrieved from Antibiotics: Origin, Nature and Properties
Tadeusz Korzybski,Zuzanna Kowszyk-Gindifer,Wlodzimierz Kurylowicz, p. 421
Viomycin is a basic peptide antibiotic, which is among the most effective agents against multidrug-resistant tuberculosis. The tuberactinomycins, such as Viomycin, target bacterial ribosomes, binding RNA and disrupting bacterial protein biosynthesis. Specifically, viomycin binds to a site on the ribosome which lies at the interface between helix 44 of the small ribosomal subunit and helix 69 of the large ribosomal subunit. The structures of this complexes suggest that the viomycin inhibits translocation by stabilizing the tRNA in the A site in the pretranslocation state.
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
15 mg/kg 1 times / day multiple, intravenous Dose: 15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 15 mg/kg, 1 times / day Co-administed with:: pyrazinamide Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: tubersulosis Age Group: 58 years Sex: M Population Size: 1 Sources: |
Other AEs: Hypomagnesemia, Hypocalcemia... |
75 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 75 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 75 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: tubersulosis Sources: |
Other AEs: Hypocalcemia, Hypokalemia... Other AEs: Hypocalcemia Sources: Hypokalemia |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypocalcemia | 15 mg/kg 1 times / day multiple, intravenous Dose: 15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 15 mg/kg, 1 times / day Co-administed with:: pyrazinamide Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: tubersulosis Age Group: 58 years Sex: M Population Size: 1 Sources: |
|
Hypokalemia | 15 mg/kg 1 times / day multiple, intravenous Dose: 15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 15 mg/kg, 1 times / day Co-administed with:: pyrazinamide Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: tubersulosis Age Group: 58 years Sex: M Population Size: 1 Sources: |
|
Hypomagnesemia | 15 mg/kg 1 times / day multiple, intravenous Dose: 15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 15 mg/kg, 1 times / day Co-administed with:: pyrazinamide Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: tubersulosis Age Group: 58 years Sex: M Population Size: 1 Sources: |
|
Hypocalcemia | 75 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 75 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 75 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: tubersulosis Sources: |
|
Hypokalemia | 75 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 75 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 75 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: tubersulosis Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Experimental studies on therapeutic effects of various combinations of antituberculosis drugs. II. Comparison of various regimens in treatment of experimental mouse tuberculosis infected with SM- and INH-resistant Schacht strain. | 1967 Jul |
|
In vitro and in vivo susceptibility of atypical mycobacteria to various drugs. | 1981 Sep-Oct |
|
A Bartter's-like syndrome from capreomycin, and a similar gentamicin tubulopathy. | 1986 Mar |
|
Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. | 1993 Sep 24 |
|
Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. | 1996 Jun |
|
Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. | 2000 Feb 1 |
|
Developing a dynamic pharmacophore model for HIV-1 integrase. | 2000 Jun 1 |
Sample Use Guides
Pulmunary tuberculosis: 30-75 mg/kg, intramuscularly, 14-182 days
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/209306
Viomycin at a concentration of 10 uM inhibits E. coli ribosomes to the extent of about 70% as measured in the poly (U) system, and to about 85% in a natural mRNA (R17) system.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C280
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
60081
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
PRIMARY | |||
|
100000079138
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
PRIMARY | |||
|
2830
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
PRIMARY | |||
|
283
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
PRIMARY | |||
|
3037981
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
PRIMARY | |||
|
VIOMYCIN
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
PRIMARY | |||
|
D014756
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
PRIMARY | |||
|
m11253
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
PRIMARY | Merck Index | ||
|
15782
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
PRIMARY | |||
|
DTXSID0023741
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
PRIMARY | |||
|
251-323-0
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
PRIMARY | |||
|
32988-50-4
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
PRIMARY | |||
|
YVU35998K5
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
PRIMARY | |||
|
SUB00078MIG
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
PRIMARY | |||
|
DB06827
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
PRIMARY | |||
|
CHEMBL1201221
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
PRIMARY | |||
|
C66654
Created by
admin on Fri Dec 15 16:15:38 UTC 2023 , Edited by admin on Fri Dec 15 16:15:38 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)